REG - Venture Life Group - Notice of General Meeting & Investor Presentation

Venture LifeAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250702:nRSB3112Pa&default-theme=true

RNS Number : 3112P  Venture Life Group PLC  02 July 2025

2 July 2025

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Notice of General Meeting

Investor Presentation via Investor Meet Company

Venture Life (AIM: VLG), a leader in product innovation, development and
commercialisation within the global consumer healthcare sector, announces that
a notice of a general meeting of the Company (the "GM") will be posted to
shareholders on 4 July 2025 together with copies of the Annual Report and
Accounts for the year ended 31 December 2024 that were published on 30 June
2025 (the "Annual Report").

The Annual Report is available in the Investor Relations section of the
Company's website at www.venture-life.com/ (http://www.venture-life.com/) ,
and the notice of GM will be made available on the same section of the
Company's website on 4 July 2025.

The GM, to lay the Annual Report before shareholders, is to be held at the
offices of Simmons & Simmons LLP, CityPoint, 1 Ropemaker Street, London,
EC2Y 9SS at 10.00 a.m. on 5 August 2025, and follows the Company's annual
general meeting held on 30 June 2025.

Investor Presentation

The Company also announces that Jerry Randall (CEO) and Daniel Wells (CFO)
will provide a presentation via Investor Meet Company relating to the final
results for the year ended 31 December 2024 at 10.00 a.m. on 3 July 2025.

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9.00 a.m. the day before the meeting or at any time during the live
presentation.

Investors can sign up to Investor Meet Company for free and add to meet
Venture Life Group plc via:

https://www.investormeetcompany.com/venture-life-group-plc/register-investor
(https://www.investormeetcompany.com/venture-life-group-plc/register-investor)

Investors who already follow Venture Life Group plc on the Investor Meet
Company platform will automatically be invited.

 

For further information, please contact:

 

 Venture Life Group PLC                                    +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cavendish Capital Markets Limited (Nomad and Broker)      +44 (0) 20 7720 0500
 Stephen Keys / George Lawson (Corporate Finance)

 Michael Johnson (Sales)

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
commercialising products for the global self-care market. Headquartered in the
UK, the Group's product portfolio includes Balance Activ in the area of
women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, plus the
Health and Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through health & beauty stores,
pharmacies, grocery multiples and e-commerce channels and are sold globally.
In the UK,  Ireland and the USA these are supplied direct by the company to
retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGFZGGNMMMGKZZ